Renal Sparing Protocols – Minimizing Risk and Maximizing Benefit in Individual Patients

Marie M. Budev DO MPH FCCP Medical Director, Lung Transplantation Cleveland Clinic



TRANSPLANT SUMMIT 2019

NO SIZE FITS ALL: Uncovering the Potential of Personalized Transplantation

FEBRUARY 21–23, 2019 • ARIZONA BILTMORE • PHOENIX, AZ

Disclosure

- No COI or Financial Disclosures
- None of the drugs I will be discussing have FDA approval for use in lung transplantation



Learning Objectives

- 1. Recognize the incidence of renal insufficiency after lung transplantation and the role of CNI in nephrotoxicity seen after lung transplantation.
- 2. Understand the potential role of certain induction agents as renal sparing therapies in the later period after lung transplantation.
- 3. Recognizing the role of mTOR Inhibitors as part of a renal sparing protocol
- 4. Understanding the utility and limitations of belatacept as a renal sparing agent



Introduction

- The advent of calcineurin inhibitors (CNI) revolutionized solid organ transplantation
 - Mitigating the risk of ACR
 - Side effects present
- CNI most common cause of nephrotoxicity
 - Hypotension, aggressive diuresis, pre tx renal insufficiency, diabetes , hyperlipidemia, hypertension
- Nephrotoxicity is most common long term medical complication after lung transplantation
 - 6 months post transplant, 91% lung tx patients have decline renal function
 - Incidence renal dysfyunction 26% 1 yr post tx, 38% 5 yrs post tx
 - Chronic renal failure (Cr > 2.5 mg/dl) occurs at incidence of 6.8% 1 yr post tx, 11% 5 yrs post tx
 - RRT long term 1.7% pts 1 yr , 3.2% pts 5 yrs
- Renal failure adversely impacts mortality


AMERICAN SOCIETY OF TRANSPLANTATION

- 4-5 fold increase in the risk of death

Transplant Proc 2017;49:2153-2160. Transplant Proc 2105;47:1966-1971. JHLT 2012;31:244-251. J Crit Care 2014;29:1028-1034.

Background

- Reality immunosuppression in lung transplantation is slow to evolve
- Increasing need for renal sparing immunosuppression
 - Older recipients
 - Sicker patients
- Several promising strategies and possibly new agents may address this issue
- Presently, CNIs continue to have a pivotal role in the immunosuppressive regimen



JHLT. 2018 Oct; 37(10): 1155-1206

JTTING EDGE of TRANSPLANTATION

AST AMERICAN SOCIETY OF

CNI

- CNI nephrotoxicity can present as acute or chronic or overlap
 - AKI dose dependent, hemodynamically mediated , reversible with dose reduction
 - CKI insidious, progressive irreversible renal interstitial fibrosis leading to impairment in function
- Tacrolimus (TAC) use advanced over the decades, target troughs have been reduced, but CKD still an issue
- Limited pharmacokinetic studies investigating TAC therapeutic dose monitoring (TDM)
- Do not accurately predict TAC exposure
 - Current TDM based on trough concentrations extrapolated from kidney and liver models
 - Limited prospective evidence to guide practice and inform the direct relationship between trough concentrations and efficacy and toxicity



AST AMERICAN SOCIETY OF TRANSPLANTATION Transplantation 2016;100:1723-1731. JHLT 2007;25:1431-1435.

TAC ER

- Extended release (ER) tacrolimus once daily administration
- No formulation approved for use in USA
 - Narrow peak trough differences (unlike with BID dosing)
 - Improve adherence

AMERICAN SOCIETY OF TRANSPLANTATION

- With increasing time in therapeutic range (TTR) may <u>reduce</u> adverse effect exposure
- Only 2 studies evaluating TAC ER in lung transplant recipients
 - studies are not outcomes based, only pharmacokinetic in nature assessing the potential for use in stable lung transplant recipients.
 - Potential for use in CF patients , gastroparesis , tx patients with early CKD
- McCormack et al –speculated once a day dosing in renal transplants improved renal function



Curr Transplant Reports 2018;5:212-219 Drugs 2014;74:2053-2064.

Induction Therapy

• Induction agents

AMERICAN SOCIETY OF TRANSPLANTATION

- Administered during <u>early</u> perioperative period to suppress T cell immune response
 - Mitigate acute rejection early
 - Delay in early utilization of CNI or lower the maintenance immunosuppressive therapy
- Role for induction therapies given <u>later</u> as renal sparing agents ?
 - CLAD/BOS type + CKD
 - CF patient gastroparesis + CKD Stage III



Basiliximab (BAS) Renal Sparing Early and Later?

- Mainly used for <u>early</u> perioperative induction
- Case reports describing <u>later</u> post tx use as renal sparing agent
- Ross et al. N=9 (2013 +/- 2051 days post tx, mean age 64.3 +/- 11.3 yrs) with Stage III B
 V CKD per MDRD Formula (III B n=2, IV n=6 V n=1),
 - n=7 CLAD <u>prior</u> to study

AMERICAN SOCIETY OF TRANSPLANTATION

- Received BAS monthly 20 mg > 6months
- Allowed lowering of TAC levels (2-4 ng/ml)
- Monitored GFR 1,3,6,12 months and FEV1
- Conclusion: During BSX treatment, eGFR Mean Slope: +0.747 +/- 0.467 (CI: +0.359) mL/min/1.73m2

No progression in CKD to ESRD

No change in FEV1 or development of DSA

1 pt CARV /BOS $\,$ II at 3 m , 1 pt died sepsis $\,$

-Demonstrated monthly BAS administration allowed for reduction in CNI therapies well tolerated

with improved eGFR over 6-12 months

Ross JD et al. JHLT 2017;36:S.411

Alemtuzumab (ALE) Induction Combined With Maintenance Immunosuppression

Single center retrospective analysis n=446(2007-2015)

- Kidney function, infectious complications, rejection, and overall survival
- 3 Pt Groups No induction (n=165), r-ATG (n=50), alemtuzumab (n=231) followed by triple drug therapy (TAC (target level depending induction agent used) + MMF + steroids)

	Calcineurin Inhabitors				Aprednisolone mg/kg		Anti-proliferative	
	No induction/ATG		Alemtuzumab		No induction /ATG	Alemtuzumab	No induction /ATG	Alemtuzumab
	CyA ng/ml	Tacrolimus ng/n	CyA ng/ml	Tacrolimus ng/ml			MM	F
0-3 months	300-350	15-18	200	10-12	0.3	0.2	1–1.5g twice a day	-
3-6 months		13-15		8-10	0.2	0.15	1–1.5g twice a day	-
6-12 months	250-300	10-12	150	6-8	0.15	0.1	1–1.5g twice a day	-
12-24 months	200	8-10	150	5-7	5 mg/d	5 mg/d	1–1.5g twice a day	1-1.5gtwice a day
>24 months	100-200	8	100-150	5			1-1.5g twice a day	

PLOS ONE 2019;14:e0210443 https//doi.org10.137/journal.pone.0210443 January 15, 2019



Results : Vienna Experience

- Pretx kidney function same in all groups
- ALE cohort had lower incidence of kidney insufficiency (GFR <60 ml/min) during all periods in the followup vs NI or rATG cohort
- Similar results were seen when eGFR calculated using MDRD formula
- All 3 cohorts showed a decrease of eGFR following transplant *

PLOS ONE 2019;14:e0210443 https//doi.org10.137/journal.pone.0210443 January 15, 2019



Long Term Kidney Function Preserved


Alemtuzumab cohort had a lower incidence of kidney insufficiency during follow up for 3 yrs , higher eGFR This is first large study that demonstrated significant differences in renal function between different induction regimens

		p-value		
	No	ATG	Alemtuzumab	
Before Tx	0.8 (0.15-8)	0.79 (0.42-1.49)	0.78 (0.23-3.2)	0.102
3 months	1.22 (0.44-3.79)	1.1 (0.54-2.1)	1.07 (0.25-3.75)	<0.001
6 months	1.42 (0.62-6.32)	1.28 (0.7-2.7)	1.22 (0.3-3.1)	<0.001
1 year	1.52 (0.63-5.74)	1.48 (0.56-3.2)	1.28 (0.47-4.2)	<0.001
2 years	1.48 (0.7-5.27)	1.48 (0.8-3)	1.24 (0.63-3.36)	<0.001
3 years	1.56 (0.7-7.38)	1.45 (0.92-4.9)	1.31 (0.37-3.05)	0.015
≥ 4 years	1.46 (0.6-7.65)	1.37 (0.85-6.89)	1.30 (0.80-3.97)	0.875

LOS ONE 2019;14:e0210443

https//doi.org10.137/journal.pone.0210443 January 15, 2019





LOS ONE 2019;14:e0210443 https//doi.org10.137/journal.pone.0210443 January 15, 2019





Other Results

Alemtuzumab Mocoszw T T Coszw B B Coszw N B Coszw N Coszw Coszw

- Incidence of infection lowest in ALE cohort
- Reversed after 1 yr NI lowest infection rate
- No difference in incidence of CMV, aspergillus and malignancies
- 1 yr Freedom from ACR highest in ALE cohort 97.7%, NI 83%, 91% ATG cohort
- 5 yr Freedom from CLAD rates highest ATG cohort 84.7%, NI 50.6%, 72.4% ALE cohort
- 1 yr and 5 yr survival rates highest for ALE cohort 87.3% and 77% (77.9% and 62.9% NI , 85.4% and 70.7% ATG cohort)

LOS ONE 2019;14:e0210443 https//doi.org10.137/journal.pone.0210443 January 15, 2019



Mammalian Targets of Rapamycin (mTOR)

- Sirolimus and everolimus
 - "non nephrotoxic " CNI replacement
- mTOR important modulator of renal disease
- mTOR inhibitors shown to prevent renal graft dysfunction by reducing glomerular hypertrophy, proinflammatory/ profibrotic cytokine production, interstitial inflammation, and fibroblast production
- Synergistic effect using lower CNI doses + mTOR
 - Preservation of renal function

AMERICAN SOCIETY OF TRANSPLANTATION

- No compromising of immunosuppression
- Risk of worsening proteinuria (majority of patients mild < 0.3 g/24hrs) but in baseline proteinuria > 0.15 g/24 hrs + significant reduced renal function → risk for nephrotic range proteinuria

Transplant Rev 2013;27:97-107 Transplantation 2016;100:2558-2568.

Combination Therapy : Renal Sparing Advantage

- Peddi et al reviewed 21 studies (2 RCT n =108 lung Tx pts) used immunosuppressive regimens that incorporate an mTOR inhibitor with TAC minimization therapy
 - Efficacy evaluated in terms of graft survival and renal function
- Conclusion: combination of mTOR + CNI had good efficacy and preservation of renal function compared to standard CNI alone
 - no changes in graft survival or rejection rates observed
 - CMV and malignancy rates low

AMERICAN SOCIETY OF TRANSPLANTATION

 Significant adverse effects seen including dyslipidemia, hypertension, proteinuria, NODM and wound healing issue in the combination group.

Transplant Rev 2013;27:97-107.



Everolimus + Reduced CNI Dosing

• 3 RCT Lung Transplantation – everolimus + low dose CNI therapy

2 RCT early everolimus with reduced CNI levels

AMERICAN SOCIETY OF TRANSPLANTATION


- <u>De novo use</u> of everolimus and lower CNIs did not impact post transplant renal deterioration
- Did not specify criteria for renal function at study entry
- 1 RCT (heart and lung tx) add on everolimus + low dose CNI <u>later</u> post transplant (NOCTET trial) > 1yr post tx
 - Enrolled mean time 52 months (? Time to development of irreversible kidney damage may enrolling earlier may be better?)
 - Moderate improvement in renal function observed after 1 and 2 yrs
 - Mean change in eGFR from baseline to 1 yr 2.3ml/min everolimus cohort and -1.3ml/min in controls (p<=0.07)
 - At last follow up > 5 yrs post randomization no between group differences and similar decline in GFR
 - High rate of pneumonia month 12 33.3% everolimus vs 9.5% control group

JHLT 2015;34:16-25. Am J Transplant 2016;16:3171-3180. Transplantation 2010 ;90:1581-1589.

A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation

- **4EVERLUNG** Efficacy of Everolimus in Combination with Specific Standard Immunosuppressive Regimen in Lung Transplant Recipients
- Prospective RCT 8 sites Germany (2012-2017)- Novartis Funding
- Aim Everolimus + low CNI dose in **Quadruple Regimen** is superior to standard triple therapy with CNI in terms of renal function
 - Unique : early initiation randomized at 3-18 months (average 10.8 m) impaired renal dysfunction (mild- mod eGFR > 50-90 ml/min per 1.73 m2) open label study

Am J Transplant 2019:00:1-11.



^a20 abnormal eGFR, 14 low eGFR, 4 leukopenia

^b4 transplant rejection, 3 leukopenia, 10 other

°1 transplant rejection/pulmonary function decline, 2 hematological abnormality, 1 worsening of general condition

FIGURE 2 CONSORT diagram. CLAD, chronic lung allograft dysfunction; CNI, calcineurin inhibitor; CONSORT, Consolidated Standards of Reporting Trials; eGFR, estimated glomerular filtration rate Am J Transplant 2019:00:1-11.

4EVERLUNG: ? For Early RI and Early Post Transplant

- Marked benefit seen subpopulation pts eGFR 40-60 ml/min per 1.73m2 → 65 ml/min per 1.73m2 (mild to moderate dysfunction)
- Early enrollment **10.8 m** window to minimize the time to dependent development of irreversible CNI nephrotoxity
- Everolimus target lower (3-8 ng/ml) compared to other earlier trials
- No signals of overimmunosuppression noted (ie infection) in the quadruple therapy group
- Discontinuation rate lower 29% vs 35-55% in other trials
- Potential benefit : Early initiation of patients with early CKD

Am J Transplant 2019:00:1-11.



Belatacept (BELA)

- Approved for use in kidney transplant to replace CNI
- BENEFIT study demonstrated higher mean GFR, graft, and patient survival compared to CSA
- Lung transplant case reports and series
 - Timofte et al. retrospective review n=8 with acute and chronic kidney disease refractory to lowering CNI or change to SRL initiation received BELA for 6 months
 - Older cohort > 65 yrs old
 - BELA initiated and CNI was withheld or reduced (median 3 doses)
 - No change in FEV1 seen or ACR episodes
 - 2 pts stable GFR, 5 pts improved GFR (mean GFR 24 ml/min/1.73m2 → 28 ml/min/ 1.73 m2 (*p=0.10*) at one month and improved up to 6 months and baseline mean Cr 3.1 to 1.7 (*p=0.05*) 1 month
 - 2 out of 3 pts IHD no longer needed IHD

Am J Transplant 2010;10:535-456 Transpl Int;2016:29:453-463.



Belatacept (BELA)

- Iasella et al. single center retrospective study in n=11 converted to BELA alone
 - All pts received induction with BAS or ALE and initial standard triple drug therapy (CNI + MMF+ steroids)
 - Converted to BELA at discretion of physician n=4 TTP, 3= PRES, 2= recurrent ACR , 1= CLAD, 1= renal sparing
 - Mean eGFR higher post BELA cohort (32.53 vs 45.26 ml/min/ m2)
 p=0.04
 - Difficult to draw conclusions regarding efficacy of BELA

Transplantation 2018;102:171-177



Personalizing Immunosuppression

- Narrow therapeutic index the limitation
 - Inter and intra patient variability
 - Genetic polymorphisms of cytochrome p450 3A enzymes and the transport protein P-glycoprotein
 - Age, clinical status , disease states , interacting medications



Summary

- Several strengths and limitations of the potential renal sparing agents and regimens
- No definitive renal sparing regimen
 - Still need to be tailored for the individual patient for maximum benefit .
 - NO "ONE SIZE FITS ALL" APPROACH!
 - Need for carefully designed and conducted clinical trials



Thank You



From the top of Camelback Mountain

